Menu
Zephex® 152a is a new, sustainable medical propellant that has been under development by Koura for several years for use in metered dose inhalers (MDIs) for treatment of respiratory disorders such as asthma and COPD.
Zephex® 152a reduces the carbon footprint of an MDI, helping to safeguard an invaluable therapeutic option for patients.
Global Warming Potential (GWP) is a measure of the atmospheric warming potential of a propellant upon release into the atmosphere. Pressurised metered-dose-inhalers using Zephex® 152a will bring about a greater than 90% reduction in GWP compared to some current MDI propellants1.
As a result, the use of Zephex® 152a will result in an environmental impact comparable to other ‘green’ technologies, including dry powder inhalers, when accounting for manufacturing, use and disposal. Utilization of the 152a molecule as a lower GWP inhaler propellant addresses concerns of both patients and pharmaceutical companies2.
Speak to a member of our team to discuss our products
